Gullo, C.* , Laverdeur, E.* , Dancre, M., Peiffer, R., Boumahd, Y., Agirman, F., Maloujahmoum, N., Désiront, L., Thiry, M., Rademaker, G., Bellahcene, A., & Peulen, O. (28 November 2025). Focal adhesion assembly and cell migration require myoferlin in PDAC cell lines. Scientific Reports, 15 (1). doi:10.1038/s41598-025-27134-2 * These authors have contributed equally to this work. |
Peiffer, R., Laverdeur, E., Gaigneaux, A., Boumahd, Y., Gullo, C., Rademaker, G., Crake, R., Lavergne, A., Maloujahmoum, N., Agirman, F., Herfs, M., Masamune, A., Letellier, E., Bellahcene, A., & Peulen, O. (2025). Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. EMBO Journal. doi:10.1038/s44318-025-00570-6 |
Anania, S., Farnir, M., Peiffer, R., Boumahd, Y., Thiry, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (17 February 2024). Identification of myoferlin as a mitochondria-associated membranes component required for calcium signaling in PDAC cell lines. Cell Communication and Signaling, 22 (1), 133. doi:10.1186/s12964-024-01514-z |
Crake, R., Gasmi, I., Dehaye, J., Lardinois, F., Peiffer, R., Maloujahmoum, N., Agirman, F., KOOPMANSCH, B., D’Haene, N., Azurmendi Senar, O., Arsenijevic, T., Lambert, F., Peulen, O., Van Laethem, J.-L., & Bellahcene, A. (17 May 2023). Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells, 12 (10), 1414. doi:10.3390/cells12101414 |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V., & Peulen, O. (02 March 2023). Correction: Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis, 12 (1), 11. doi:10.1038/s41389-023-00455-5 |
Mouziane, L., Crake, R., Maloujahmoum, N., Agirman, F., Roncarati, P., Herfs, M., & Bellahcene, A. (30 September 2022). Characterisation of methylglyoxal stress in human colorectal cancer and liver metastases using immunohistochemistry [Poster presentation]. BACR, Gent, Belgium. |
Rademaker, G.* , Boumahd, Y.* , Peiffer, R., Anania, S., Wissocq, T., Liégeois, M., Luis, G., Sounni, N. E., Agirman, F., Maloujahmoum, N., De Tullio, P., Thiry, M., Bellahcene, A., Castronovo, V., & Peulen, O. (July 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biology, 53, 102324. doi:10.1016/j.redox.2022.102324 * These authors have contributed equally to this work. |
Boumahd, Y., Rademaker, G., Peiffer, R., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., & Peulen, O. (22 June 2022). Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells [Poster presentation]. EACR 2022. |
Rademaker, G., Costanza, B., Pyr Dit Ruys, S., Peiffer, R., Agirman, F., Maloujahmoum, N., Vertommen, D., Turtoi, A., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2022). Paladin, overexpressed in colon cancer, is required for actin polymerisation and liver metastasis dissemination. Oncogenesis, 11, 42. doi:10.1038/s41389-022-00416-4 * These authors have contributed equally to this work. |
Crake, R., Agirman, F., Arsenijevic, T., Maloujahmoum, N., Peulen, O., Van Laethem, J.-L., & Bellahcene, A. (14 October 2021). Improving pancreatic cancer response to gemcitabine by overcoming methylglyoxal driven suppression of AMPK [Poster presentation]. GIGA-Cancer Day, Liege, Belgium. |
Luis, G.* , Godfroid, A.* , Nishiumi, S., Cimino, J., Blacher, S., Maquoi, E., Wery, C., Collignon, A., Longuespée, R., MONTERORUIZ, L., Dassoul, I., Maloujahmoum, N., Pottier, C., Mazzucchelli, G., De Pauw, E., Bellahcene, A., Yoshida, M., Noël, A., & Sounni, N. E. (2021). Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biology, 43, 102006. doi:10.1016/j.redox.2021.102006 * These authors have contributed equally to this work. |
Anania, S., Peiffer, R., Rademaker, G., Hego, A., Thiry, M., Deldicque, L., Francaux, M., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (21 June 2020). Myoferlin is a yet unknown interactor of the mitochondrial dynamics’ machinery in pancreas cancer cells. Cancers, 12 (6), 1643. doi:10.3390/cancers12061643 |
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., KOOPMANSCH, B., MacKay, G. M., Chiavarina, B., Costanza, B., Rademaker, G., Durieux, F., Agirman, F., Maloujahmoum, N., Cusumano, P. G., LOVINFOSSE, P., Leung, H. Y., LAMBERT, F., Bours, V., ... Bellahcene, A. (04 February 2020). Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. Cell Reports, 30 (5), 1400-1416.e6. doi:10.1016/j.celrep.2020.01.012 |
Anania, S., Rademaker, G., Peiffer, R., Hego, A., Deldicque, L., Maloujahmoum, N., Agirman, F., Bellahcene, A., Castronovo, V., & Peulen, O. (February 2020). Role of myoferlin in mitochondrial dynamics and metabolic fitness of pancreas cancer [Poster presentation]. BACR Annual Meeting 2020 - Cancer metastases: from bedside to bench, Brussels, Belgium. |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (26 November 2019). Myoferlin depletion induces DNA damage response and p53- dependent cell cycle arrest and apoptosis in colon cancer [Poster presentation]. Metabolism in Cancer and Stromal Cells (2nd edition), Leuven, Belgium. |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (23 October 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Pancreatic Cancer Symposium, Toulouse, France. |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Bellahcene, A., Castronovo, V., & Peulen, O. (13 June 2019). Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity Through the Control of Oxidative Phosphorylation [Poster presentation]. Belgian Society for Cell and Developmental Biology - Spring Meeting, Liège, Belgium. |
Rademaker, G., Costanza, B., Anania, S., Agirman, F., Maloujahmoum, N., Di Valentin, E., Goval, J.-J., Bellahcene, A., Castronovo, V., & Peulen, O. (June 2019). Myoferlin contributes to the metastatic phenotype of pancreatic cancer cells by enhancing their migratory capacity through the control of oxidative phosphorylation. Cancers, 11 (6). doi:10.3390/cancers11060853 |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2019). Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis. doi:10.1038/s41389-019-0130-6 * These authors have contributed equally to this work. |